Dr. Mihir Wagh, MD
Claim this profileUniversity of Colorado - Anschutz Medical Campus
Studies Barrett's Esophagus
Studies Esophageal Cancer
4 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Mihir Wagh, MD is currently running
EUS-FNA With/Without MFB
for Pancreatic Cysts
Pancreatic cystic lesions (PCLs) are a common incidental finding in cross sectional imaging (up to 27% on CT scan and 41% on MRI) and pose a management challenge to physicians. According to society guidelines, PCLs with specific features should prompt additional workup with endoscopic ultrasound (EUS) for cyst characterization as well as cyst sampling. This can help determine if the cyst is mucinous or non-mucinous which has implications for its malignant potential. Cyst fluid has traditionally been sampled using EUS with fine needle aspiration (EUS-FNA) and sent for fluid analysis and cytology. More recently, the adjunctive use of the through-the-scope micro forceps (Moray micro forceps, US Endoscopy, Mentor, OH) biopsy (EUS-MFB) has shown promise for diagnosis of PCLs. This technology utilizes a micro forceps through a 19-gauge needle to biopsy the cyst wall for histology, in addition to collecting cyst fluid for CEA level and cytology. More recently, the adjunctive use of the Moray® through the needle micro forceps biopsy (EUS-MFB) has shown promise for diagnosis of PCLs. This technology utilizes a micro forceps through a 19-gauge needle to biopsy the cyst wall for histology, in addition to collecting cyst fluid for CEA level and cytology. Only a few small retrospective reports have been published regarding the use of MFB. The results of this study will hopefully help increase diagnostic yield by obtaining a histopathologic diagnosis of these PCLs, and potentially affect practice patterns of gastroenterologists and the endoscopic community, specifically those physicians who perform EUS in these patients. Furthermore, the results will help determine whether there is reason to continue this line of research to obtain a definite histologic tissue diagnosis of PCLs.
Recruiting1 award N/A2 criteria
WATS3D vs Seattle Protocol
for Barrett's Esophagus
The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampling (WATS3D). Barrett's esophagus is a common condition that is used to spot patients at increased risk of developing a type of cancer in the esophagus (swallowing tube) called esophageal adenocarcinoma. The 5-year survival rate is as low as 18% for patients who get esophageal adenocarcinoma, but the rate may be improved if the cancer is caught in its early stages. Barrett's esophagus can lead to dysplasia, or precancerous changes, which occurs when cells look abnormal but have not developed into cancer. If the abnormal cells increase from being slightly abnormal (low-grade dysplasia), to being very abnormal (high-grade dysplasia), the risk of developing cancer (esophageal adenocarcinoma) goes up. Therefore, catching dysplasia early is very important to prevent cancer. Endoscopic surveillance is a type of procedure where endoscopists run a tube with a light and a camera on the end of it down a patients throat and remove a small piece of tissue. The piece of tissue, called a biopsy, is about the size of the tip of a ball-point pen and is checked for abnormal cells and cancer cells. Patients are being asked to be in this research study because they have been diagnosed with BE or suspected to have BE, and will need an esophagogastroduodenoscopy (EGD). Patients with BE undergo sampling using the Seattle biopsy protocol during which samples are obtained from the BE in a four quadrant fashion every 2 cm along with target biopsies from any abnormal areas within the BE. Another sampling approach is WATS3D which utilizes brushings from the BE. While both of these procedures are widely accepted approaches to sampling patients with BE during endoscopy, there is not enough research to show if one is better than the other. Participants in this study will undergo sampling of the BE using both approaches (Seattle biopsy protocol and WATS-3D); the order of the techniques will be randomized. Up to 2700 participants will take part in this research. This is a multicenter study involving several academic, community and private hospitals around the country.
Recruiting1 award N/A
More about Mihir Wagh, MD
Clinical Trial Related7 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Mihir Wagh, MD has experience with
- Seattle Protocol
- WATS3D Brushings
- EUS-FNA Alone
- EUS-FNA Plus MFB
- Endoscopic Tissue Apposition
- AGBS
Breakdown of trials Mihir Wagh, MD has run
Barrett's Esophagus
Esophageal Cancer
Adenocarcinoma
Pancreatic Cyst
Endoscopic Tissue Apposition
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mihir Wagh, MD specialize in?
Mihir Wagh, MD focuses on Barrett's Esophagus and Esophageal Cancer. In particular, much of their work with Barrett's Esophagus has involved treating patients, or patients who are undergoing treatment.
Is Mihir Wagh, MD currently recruiting for clinical trials?
Yes, Mihir Wagh, MD is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Mihir Wagh, MD has studied deeply?
Yes, Mihir Wagh, MD has studied treatments such as Seattle protocol, WATS3D brushings, EUS-FNA Alone.
What is the best way to schedule an appointment with Mihir Wagh, MD?
Apply for one of the trials that Mihir Wagh, MD is conducting.
What is the office address of Mihir Wagh, MD?
The office of Mihir Wagh, MD is located at: University of Colorado - Anschutz Medical Campus, Aurora, Colorado 80045 United States. This is the address for their practice at the University of Colorado - Anschutz Medical Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.